tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
PremiumThe FlyRallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
1M ago
Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102
Premium
The Fly
Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102
1M ago
Rallybio Finalizes Employment Agreement with CMO
Premium
Company Announcements
Rallybio Finalizes Employment Agreement with CMO
2M ago
Rallybio Reports Q1 2025 Financial Results and Strategic Updates
PremiumCompany AnnouncementsRallybio Reports Q1 2025 Financial Results and Strategic Updates
3M ago
Rallybio reports Q1 EPS (21c), consensus (28c)
Premium
The Fly
Rallybio reports Q1 EPS (21c), consensus (28c)
4M ago
Rallybio downgraded to Hold from Buy at JonesResearch
Premium
The Fly
Rallybio downgraded to Hold from Buy at JonesResearch
4M ago
Rallybio discontinues RLYB212 program
PremiumThe FlyRallybio discontinues RLYB212 program
5M ago
Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
Premium
Ratings
Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
5M ago
Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
Premium
Ratings
Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100